Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Complications Clear all
Completed Phase 2 Interventional

Dactinomycin in Treating Patients With Persistent or Recurrent Gestational Trophoblastic Neoplasia

NCT00003688
View directory record Official record
Conditions
Gestational Trophoblastic Tumor
Interventions
dactinomycin
Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
12 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
28
States / cities
Birmingham, Alabama • Los Gatos, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

Tabectedin to Treat Children and Adolescents With Cancer

NCT01453283
View directory record Official record
Conditions
Solid Tumors
Interventions
Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

NCT05457283
View directory record Official record
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Not applicable Interventional

Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes

NCT02548494
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetic Ketoacidosis
Interventions
Glargine, IV insulin, Electrolyte Correction, Correction of Fluid Loss
Drug · Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
1 Year to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional

A Postpartum Adaptation Study of the Connecting and Reflecting Experience Parenting Program

NCT06042166
View directory record Official record
Conditions
Postpartum Depression, Postpartum Anxiety, Parenting Stress, Parent Child Relationships
Interventions
Connecting and Reflecting Experience (CARE) Program
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Terminated Phase 2 Interventional Results available

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

NCT04871529
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Interventions
Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride, Carboplatin
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
92
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Orlando, Florida + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2024 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

NCT00659646
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge and levofloxacin, Levofloxacin only
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy

NCT02077140
View directory record Official record
Conditions
Postoperative Pain
Interventions
MDT-10013, Standard of care for pain
Drug
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years to 80 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Phoenix, Arizona • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Jul 23, 2026, 2:45 AM EDT
Recruiting Phase 4 Interventional

Perineal Massage Using A Pelvic Wand During Pregnancy

NCT06986824
View directory record Official record
Conditions
Pregnancy Related, Pelvic Floor Disorders, Obstetric; Injury, Patient Empowerment
Interventions
Pelvic wand
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

NCT00002474
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, cyclophosphamide, mitoxantrone hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support
Drug · Procedure
Lead sponsor
Loyola University
Other
Eligibility
Up to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2005
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Caspofungin Acetate in Treating Children With Fever and Neutropenia

NCT00020527
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions
caspofungin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Not listed No phase listed Observational

Adherence to Preventive Care for Cervical Cancer

NCT02406391
View directory record Official record
Conditions
Cervical Cancer, Cervical Precancer, Adherence
Interventions
Not listed
Lead sponsor
Brookdale University Hospital Medical Center
Other
Eligibility
21 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Brooklyn, New York • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional Results available

Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00459290
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
mifepristone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Jul 23, 2026, 2:45 AM EDT
Withdrawn Not applicable Interventional

Animal Assisted Intervention for Hemodialysis Outpatients

NCT06030050
View directory record Official record
Conditions
End-Stage Kidney Disease, Chronic Kidney Failure, Chronic Pain
Interventions
Animal-assisted intervention
Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional Results available

Low Doses of Aspirin in the Prevention of Preeclampsia

NCT04070573
View directory record Official record
Conditions
Preeclampsia
Interventions
acetylsalicylic acid
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT00126542
View directory record Official record
Conditions
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)

NCT00072046
View directory record Official record
Conditions
Kidney Cancer
Interventions
bevacizumab, recombinant interferon alfa
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
489
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 341 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 2 Interventional

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

NCT00134186
View directory record Official record
Conditions
Carcinoma, Renal Cell, Urogenital Neoplasms, Urologic Neoplasms, Kidney Neoplasms
Interventions
motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2007 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

NCT00005046
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
chemotherapy, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
21 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
5
States / cities
Orange, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes

NCT01719029
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Low-Carbohydrate/Higher Fat Diet, High Carbohydrate/Low fat diet
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Not applicable Interventional

Group Therapy for Postpartum Depression

NCT00051246
View directory record Official record
Conditions
Depression, Postpartum
Interventions
Mother-Infant Group Psychotherapy, Interpersonal Psychotherapy
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Jul 23, 2026, 2:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection

NCT03174795
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
RO7079901, Meropenem
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
2
States / cities
La Mesa, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Jul 23, 2026, 2:45 AM EDT
Completed Phase 3 Interventional

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

NCT00977483
View directory record Official record
Conditions
Diabetic Polyneuropathy
Interventions
Thioctic Acid, Placebo
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
18 Years to 64 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jul 23, 2026, 2:45 AM EDT